StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
LTGOLatigo Biotherapeutics, Inc.
stockpulse.co.kr
Nasdaq
$14.88▼ 0.27%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 9.3After-hours26.09.04 05:32
    10-QEarnings#●●●#●●●

    Latigo Biotherapeutics, Inc.

    Latigo Biotherapeutics, Inc. has filed its quarterly report (Form 10-Q) for the period ended June 30, 2026. As of September 1, 2026, the company had 66,299,347 shares of common stock outstanding.…more

    $14.88-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.3After-hours26.09.04 05:15
    8-KKey event

    Latigo Biotherapeutics, Inc.

    Latigo Biotherapeutics raised $397.4 million in gross proceeds through an upsized IPO in August 2026, with current cash expected to fund operations into 2029. The company reported a net loss of $25.8 million for the second quarter of 2026 and is advancing its lead candidate, onzotrigine, into Phase 3 clinical trials.…more

    $14.88-0.27%vs prev close
    View filingShare
  • 8.18After-hours26.08.19 07:17
    SCHEDULE 13GOwnership

    Latigo Biotherapeutics, Inc.

    AI Biotechnology LLC has filed a Schedule 13G, disclosing its status as a major shareholder with more than 5% ownership in Latigo Biotherapeutics, Inc. This filing confirms that the investor has acquired a significant stake capable of influencing the company's corporate governance.…more

    $14.88-0.27%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.3After-hours26.09.04 06:04
    #●●●#●●●

    Latigo Biotherapeutics Reports Q2 Loss of $27.59 Per Share

    Latigo Biotherapeutics reported a quarterly loss of $27.59 per share, showing an improvement compared to the previous year's loss. However, the company recorded zero sales for the quarter, maintaining a neutral outlook.…more

    $14.88-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.3After-hours26.09.04 05:05

    ●●●●●●●● ●●●●● ●●●●●●

    Latigo Biotherapeutics raised approximately $397.4 million through an upsized IPO, securing operating capital through 2029. While the company reported progress in its non-opioid pain pipeline and key leadership appointments, it continues to post significant net losses.…more

    $14.88-0.27%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →